Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Repatha | evolocumab | Primary hyperlipidemia | Active | |||
Repatha | Evolocumab | Primary hyperlipidemia and mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
Oxlumo | lumasiran | Primary hyperoxaluria type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Active | ||
Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete |